Voyager Therapeutics (VYGR) Operating Expenses (2014 - 2026)

Voyager Therapeutics has disclosed Operating Expenses across 13 years of filings, most recently posting $32.9 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $32.9 million, down 20.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $163.9 million (down 2.87% YoY), and the FY2025 annual result was $172.2 million, up 5.47% from the prior year.
• Operating Expenses came in at $32.9 million for Q1 2026 at Voyager Therapeutics, down from $45.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $45.3 million in Q4 2025 to a low of $20.1 million in Q2 2022.
• The 5-year median for Operating Expenses is $35.7 million (2024), against an average of $34.6 million.
• Across the five-year window, Operating Expenses plunged 32.94% in 2022 and surged 56.42% in 2023, its largest moves.
• Voyager Therapeutics' Operating Expenses stood at $23.0 million in 2022, then soared by 56.42% to $36.0 million in 2023, then increased by 23.83% to $44.6 million in 2024, then advanced by 1.55% to $45.3 million in 2025, then declined by 27.4% to $32.9 million in 2026.
• The last three Operating Expenses figures came in at $32.9 million (Q1 2026), $45.3 million (Q4 2025), and $44.0 million (Q3 2025), per Business Quant data.